Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
Crossref DOI link: https://doi.org/10.1007/s13300-018-0402-8
Published Online: 2018-03-19
Published Print: 2018-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wilkinson, Lars
Hunt, Barnaby
Johansen, Pierre
Iyer, Neeraj N.
Dang-Tan, Tam
Pollock, Richard F.
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 3 February 2018
First Online: 19 March 2018